Maluther DS

Maluther DS (Double Strength) is a fixed-dose Artemisinin-based Combination Therapy (ACT) antimalarial containing two synergistic active ingredients: artemether and lumefantrine.

• Artemether: A fast-acting semi-synthetic endoperoxide derivative of artemisinin. Upon interaction with intra-parasitic heme iron, it generates reactive oxygen species (free radicals) that rapidly destroy essential parasitic proteins and lipids, achieving prompt clearance of blood-stage parasites and fever relief within hours.

• Lumefantrine: A long-acting lipophilic aryl-amino alcohol derivative. It acts by inhibiting the conversion of toxic free heme into inert hemozoin inside the parasite’s food vacuole. The accumulated toxic heme destroys parasitic cell membranes, clearing residual parasites and preventing disease recrudescence.

The Double Strength (DS) formulation combines higher concentrations of active ingredients (80 mg artemether / 480 mg lumefantrine per tablet compared to standard 20 mg / 120 mg tablets), lowering the total pill count for adults from 24 tablets down to just 6 tablets total over the 3-day treatment course.

Primary Medical Indications

Maluther DS is indicated for adult and adolescent populations (weighing 35 kg or more) for the treatment of acute parasitic infections:

• Uncomplicated Plasmodium falciparum Malaria: First-line curative treatment for acute, uncomplicated malaria caused by P. falciparum or mixed species infections containing P. falciparum.

• Multi-Drug Resistant Malaria: Highly effective against P. falciparum strains exhibiting resistance to older antimalarial monotherapies such as chloroquine, sulfadoxine-pyrimethamine (Fansidar), or quinine.

• Treatment of Non-falciparum Blood-Stage Parasites: Effective against erythrocytic schizonts of Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae (radical cure for liver hypnozoites in P. vivax and P. ovale requires adjunct therapy with primaquine or tafenoquine).

Key Product Specifications & Dosing Forms

Critical Safety Guidelines & Precautions

• Must Be Taken with High-Fat Food or Milk: Lumefantrine is highly lipophilic and relies heavily on dietary fat for gastrointestinal absorption. Taking Maluther DS on an empty stomach drastically lowers drug exposure, risking therapeutic failure and disease relapse.

• Re-Dosing Protocol for Vomiting: If vomiting occurs within 1 hour of administration, a full replacement dose must be taken immediately. If persistent vomiting prevents oral retention, transition the patient to parenteral therapy (e.g., IV or IM artesunate).

• QTc Prolongation Warning: Lumefantrine has the potential to prolong the QTc interval on an ECG. Avoid concurrent use with other QT-prolonging drugs (e.g., macrolide antibiotics, antiarrhythmics, quinine, halofantrine) or in patients with congenital long QT syndrome.

• Not for Severe/Complicated Malaria: Contraindicated as monotherapy for severe or complicated malaria (e.g., cerebral malaria, severe malarial anemia, pulmonary edema). Severe cases require emergency hospital admission and intravenous antimalarial intervention.

• Prophylaxis Restriction: Maluther DS is strictly a therapeutic curative agent and must never be used for malaria prophylaxis.